Business
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 Cash balance of $23.9 million as of March 31, 2026 anticipated to fund operations into 2027, including completion of the dose escalation portion of the ongoing BDC-4182 Phase 1/2 study REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment
About this update from Bolt Biotherapeutics, Inc.
[{"type":"image","alt":"Bolt Biotherapeutics, Inc.","displaySize":"","headline":null,"caption":"Bolt Biotherapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":166,"height":74,"url":"https://media.zenfs.com/en/globenewswire.com/7c034fa4294bd392e965b4cf4a9ef25c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PIPaI3UaLPpJb6VD5RYb0w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTk0O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/7c034fa4294bd392e965b4cf4a9ef25c","width":166,"height":74},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/PIPaI3UaLPpJb6VD5RYb0w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTk0O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/7c034fa4294bd392e965b4cf4a9ef25c","width":166,"height":74}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026","length":128,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash balance of $23.9 million as of March 31, 2026 anticipated to fund operations into 2027, including completion of the dose escalation portion of the ongoing BDC-4182 Phase 1/2 study","length":184,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":312,"olType":false},{"type":"text","content":"REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.","length":310,"tagName":"p"},{"type":"text","content":"“We are encouraged by what we have seen thus far in patients treated with BDC-4182, a next-generation Boltbody™ ISAC. BDC-4182 has a unique mechanism of action that has the potential to combine the power of ADCs with the durability of T-cell engagers and unlock a new frontier in cancer treatment,” said Willie Quinn, President and Chief Executive Officer. “We continue to enroll patients with gastric and gastroesophageal cancer in our ongoing clinical trial, and we look forward to reporting initial data in the third quarter of 2026.”","length":537,"tagName":"p"},{"type":"text","content":"Recent Highlights and Anticipated Milestones ","length":44,"tagName":"p"},{"type":"list","items":[{"val"...